Biotheus Inc. and Hansoh Pharma Expand Strategic Collaboration for Cancer Treatment Advancements

Biotheus Inc. (Biotheus), a prominent clinical-stage biotech company specializing in biologics for oncology and inflammatory diseases, and Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma), China’s leading innovation-driven pharmaceutical company, have announced an extension of their strategic collaboration, building upon their existing partnership since 2022. The collaboration aims to advance cancer treatment through the development of antibody-drug conjugate products (ADC Product) utilizing Biotheus’ proprietary anti-EGFR/cMet bispecific antibody PM1080/HS-20117.

As per the agreement, Hansoh Pharma will receive exclusive worldwide rights from Biotheus to utilize PM1080/HS-20117 for the development, production, and commercialization of ADC Products, with sublicensing rights. Biotheus stands to receive up to 5 billion RMB in upfront and success-based milestones for ADC Products, along with tiered royalties based on global net sales from Hansoh Pharma.

PM1080/HS-20117, currently undergoing phase I clinical trials, is a 1+1 heterodimeric structure of EGFR/cMet bispecific antibody. It targets tumor antigens EGFR and cMet, inhibiting tumor growth and survival, with potential applications in treating various solid tumors.

Mr. Xiaolin Liu, Co-founder, Chairman, and Chief Executive Officer of Biotheus, expressed appreciation for Hansoh’s confidence in PM1080’s potential, stating, “Bispecific ADCs have a potential advantage for better tumor enrichment, overall efficacy and safety. Through this collaboration, we hope to develop a novel EGFR/cMet bispecific ADC with better efficacy and safety for cancer patients worldwide.”

Ms. Eliza Sun, Executive Director of the Board at Hansoh, highlighted the synergies between Hansoh’s ADC expertise and Biotheus’ antibody capabilities, expressing confidence in the potential clinical benefits of the collaboration. She emphasized Hansoh’s commitment to providing transformative treatment options to cancer patients globally.

Biotheus Inc. is dedicated to discovering, developing, and delivering novel antibodies to address unmet medical needs in oncology and inflammatory diseases. Hansoh Pharma, a leading pharmaceutical company in Greater China, is committed to innovation in treating major diseases, including oncology.

Related posts:

Hengrui Pharma Teams Up with Merck KGaA for Cancer Therapies AbelZeta Pharma, Inc. Establishes Scientific Advisory Board to Propel Advancements in Inflammatory and Immunological Diseases Sumitomo Pharma’s ORGOVYX Receives Health Canada Approval for Advanced Prostate Cancer Treatment BridGene Biosciences and Galapagos NV Join Forces in Landmark Collaboration for Oncology Drug Discovery